In 2015, James Larkin et al. demonstrated for the first time that combining the CTLA-4 inhibitor Ipilimumab with the PD-1/PD-L1 inhibitor Nivolumab significantly extended the survival of patients with advanced melanoma [165]. This evidence concerns the gene PDCD1 and melanoma.